Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Merck & Company (GB:0QAH)
LSE:0QAH
Holding GB:0QAH?
Track your performance easily
0QAH Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$99.80 - $152.06
Previous Close$108.9
Volume41.05K
Average Volume (3M)13.73K
Market Cap
$278.20B
Enterprise Value$304.70B
Total Cash (Recent Filing)$11.35B
Total Debt (Recent Filing)$37.79B
Price to Earnings (P/E)20.3
Beta0.36
Next Earnings
Oct 31, 2024EPS Estimate
$1.53Last Dividend Ex-Date
Sep 16, 2024Dividend Yield2.81%
Share Statistics
EPS (TTM)5.39
Shares Outstanding2,534,809,312
10 Day Avg. Volume30,880
30 Day Avg. Volume13,732
Standard Deviation0.06
R-Squared0.08
Alpha0.00985
Financial Highlights & Ratios
Price to Book (P/B)1.76
Price to Sales (P/S)4.45
Price to Cash Flow (P/CF)12.30
P/FCF Ratio14.40
Enterprise Value/Market CapN/A
Enterprise Value/Revenue4.88
Enterprise Value/Gross Profit6.93
Enterprise Value/Ebitda15.66
Forecast
1Y Price Target
$137.73Price Target Upside26.47% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering19
Merck & Company News
Bulls Say, Bears Say
Bulls Say
Drug Approval And Market PositionMRK reported positive top-line data with clesrovimab meeting its primary efficacy and safety endpoints, including reducing medically attended lower respiratory infections caused by RSV.
Earnings And Financial PerformanceMerck could still meet the $16.5 billion topline expectation due to Keytruda strength and Winrevair upside.
Product Growth And ExpansionExcluding China, Gardasil sales showed double-digit growth in the previous quarter, indicating steady growth potential for the rest of the year.
Bears Say
Earnings And Sales ProjectionsEPS estimates were lowered reflecting IPR&D charges and a lower Gardasil estimate.
Product Performance In ChinaConcerns over Gardasil's (G9's) near-term growth within China (60-70% of ex-US G9 sales) was an unpleasant surprise that dampens MRK's growth.
Vaccine CompetitionThe biggest reason for slowing Gardasil sales is that the bivalent vaccine is taking share, driven primarily by the bivalent being provided for free by local governments and charity organizations.
---
Options Prices
Currently, No data available
---
Ownership Overview
0.04% Insiders
21.50% Mutual Funds
1.60% Other Institutional Investors
56.60% Public Companies and
Individual Investors
0QAH FAQ
What was Merck & Company’s price range in the past 12 months?
Merck & Company lowest share price was $99.80 and its highest was $152.06 in the past 12 months.
What is Merck & Company’s market cap?
Currently, no data Available
When is Merck & Company’s upcoming earnings report date?
Merck & Company’s upcoming earnings report date is Oct 31, 2024 which is in 12 days.
How were Merck & Company’s earnings last quarter?
Merck & Company released its earnings results on Jul 30, 2024. The company reported $2.28 earnings per share for the quarter, beating the consensus estimate of $2.168 by $0.112.
Is Merck & Company overvalued?
According to Wall Street analysts Merck & Company’s price is currently Undervalued.
Does Merck & Company pay dividends?
Merck & Company pays a Quarterly dividend of $0.77 which represents an annual dividend yield of 2.81%. See more information on Merck & Company dividends here
What is Merck & Company’s EPS estimate?
Merck & Company’s EPS estimate is $1.53.
How many shares outstanding does Merck & Company have?
Merck & Company has 2,534,809,300 shares outstanding.
What happened to Merck & Company’s price movement after its last earnings report?
Merck & Company reported an EPS of $2.28 in its last earnings report, beating expectations of $2.168. Following the earnings report the stock price went down -9.127%.
Which hedge fund is a major shareholder of Merck & Company?
Among the largest hedge funds holding Merck & Company’s share is Fisher Asset Management LLC. It holds Merck & Company’s shares valued at 2B.
---
Merck & Company Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$137.73 (26.47% Upside)
$137.73 (26.47% Upside)
Blogger Sentiment
Bullish
GB:0QAH Sentiment 89%
Sector Average 70%
Sector Average 70%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
9.40%
12-Months-Change
Fundamentals
Return on Equity
33.39%
Trailing 12-Months
Asset Growth
7.81%
Trailing 12-Months
Company Description
Merck & Company
Merck & Co., Inc. develops pharmaceutical and vaccine products. It also offers healthcare solutions and vaccines addressing animal health. The company was founded in 1891 and is headquartered in Kenilworth, NJ.
---
0QAH Company Deck
---
0QAH Earnings Call
Q2 2024
0:00 / 0:00
---
0QAH Sales Breakdown
45.91% Oncology
22.09% Vaccines
5.64% Hospital Acute Care
5.60% Diabetes
20.75% Other
---
0QAH Stock 12 Month Forecast
Average Price Target
$137.73
▲(26.47% Upside)
Technical Analysis
Best Analysts Covering 0QAH
1 Year
1 Year Success Rate
27/40 ratings generated profit
1 Year Average Return
+11.98%
reiterated a buy rating last month
Copying Daina Graybosch's trades and holding each position for 1 Year would result in 67.50% of your transactions generating a profit, with an average return of +11.98% per trade.
---